Atea Pharmaceuticals (AVIR) Competitors $3.04 -0.10 (-3.18%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.08 +0.04 (+1.48%) As of 05:58 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. SION, ORIC, PHAR, SYRE, SPRY, PRAX, QURE, ATAI, CRON, and CRMDShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), uniQure (QURE), atai Life Sciences (ATAI), Cronos Group (CRON), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure atai Life Sciences Cronos Group CorMedix Sionna Therapeutics (NASDAQ:SION) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk. Does the media prefer SION or AVIR? In the previous week, Sionna Therapeutics had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Sionna Therapeutics and 3 mentions for Atea Pharmaceuticals. Sionna Therapeutics' average media sentiment score of 0.84 beat Atea Pharmaceuticals' score of 0.75 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SION or AVIR more profitable? Sionna Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Atea Pharmaceuticals N/A -32.55%-30.47% Do institutionals and insiders have more ownership in SION or AVIR? 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 3.9% of Sionna Therapeutics shares are held by company insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate SION or AVIR? Sionna Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 70.33%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 97.37%. Given Atea Pharmaceuticals' higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation and earnings, SION or AVIR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AAtea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.89 SummarySionna Therapeutics beats Atea Pharmaceuticals on 8 of the 11 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$249.18M$3.15B$5.80B$10.16BDividend YieldN/A2.32%5.72%4.60%P/E Ratio-1.8921.2475.0826.39Price / SalesN/A420.70508.41175.01Price / CashN/A44.4425.8129.91Price / Book0.589.6413.596.28Net Income-$168.38M-$53.20M$3.29B$270.38M7 Day Performance-3.80%0.07%0.07%1.89%1 Month Performance-13.14%4.27%4.57%6.01%1 Year Performance-21.85%9.62%76.79%25.26% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.0713 of 5 stars$3.04-3.2%$6.00+97.4%-21.4%$249.18MN/A-1.8970Positive NewsShort Interest ↑SIONSionna Therapeutics2.8249 of 5 stars$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035Gap UpHigh Trading VolumeORICOric Pharmaceuticals4.5562 of 5 stars$10.50-3.5%$17.29+64.6%+8.3%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.2232 of 5 stars$14.80-3.0%$30.00+102.7%+82.9%$1.05B$297.20M-113.85280News CoverageSYRESpyre Therapeutics2.5077 of 5 stars$16.63-2.2%$53.40+221.1%-49.5%$1.03B$890K-4.8973News CoverageSPRYARS Pharmaceuticals2.5021 of 5 stars$10.70+6.3%$32.50+203.7%-25.1%$995.18M$89.15M-21.8490Positive NewsPRAXPraxis Precision Medicines2.4772 of 5 stars$40.75-13.0%$85.88+110.7%-32.4%$985.99M$8.55M-3.32110Positive NewsHigh Trading VolumeQUREuniQure3.2223 of 5 stars$17.43-2.9%$37.45+114.9%+162.2%$984.86M$27.12M-4.45500ATAIatai Life Sciences2.8907 of 5 stars$4.52-1.1%$11.25+148.9%+257.7%$979.53M$2.31M-6.5580CRONCronos Group2.4926 of 5 stars$2.48-0.8%N/A+17.0%$957.23M$117.61M49.60450CRMDCorMedix3.9113 of 5 stars$12.75+2.8%$17.33+35.9%+82.0%$925.65M$43.47M17.0030Analyst Upgrade Related Companies and Tools Related Companies Sionna Therapeutics Alternatives Oric Pharmaceuticals Alternatives Pharming Group Alternatives Spyre Therapeutics Alternatives ARS Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives uniQure Alternatives atai Life Sciences Alternatives Cronos Group Alternatives CorMedix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersNew Biotech Backed by Proven Incubator Now Open to PublicA successful biotech incubator just opened its next chapter - and you're invited to their raise. This deal ...i2i Marketing Group, LLC | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredDalio’s $319 Million Gold BetA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf you own dollars, read this...Former Goldman Exec: "A Strange Day Is Coming to America" Dr. David Eifrig, who warned of inflation months ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVIR Stock Alerts